echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Nutrition News > Cell-derived therapy may help repair abnormal heart rhythms

    Cell-derived therapy may help repair abnormal heart rhythms

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The research, published in the European Heart Journal, could lead to a new approach to treating heart rhythm problems known as ventricular arrhythmias -- the leading cause of sudden cardiac death
    .
    In an accompanying editorial, experts describe the research as "completely upending the field

    .
    "

    Repair damaged heart

    After myocardial infarction damages tissue, ventricular arrhythmias can occur, causing confusion in the electrical patterns in the lower chambers of the heart
    .
    The heart beats too fast to support blood circulation, resulting in insufficient blood flow and, if not treated, death

    .

    Current treatments for ventricular arrhythmias caused by heart attacks are far from ideal
    .
    These include medication with severe side effects, implanted devices that provide internal shock, and a procedure called radiofrequency ablation, in which parts of the heart are deliberately damaged to interrupt damaging electrical signals

    .
    Unfortunately, all of these diseases have a high recurrence rate

    .

    "Ablation is a counterintuitive approach because you're destroying the heart muscle of an already fragile heart," said Eugenio Cingolani, MD,
    director of the Cardiac Genetics-Familial Arrhythmia Program at the Smidt Heart Institute in Cedars-Sinai.
    , who is also the senior author of the study

    .
    "We asked ourselves, 'What if we were trying to repair damaged tissue instead of destroying it?'"

    With that in mind, the team tried a different approach in lab pigs that had experienced heart attacks
    .
    They injected some laboratory pigs with tiny balloon-like vesicles (called exosomes) produced by cardiosphere-derived cells (cdc), which are progenitor cells from human heart tissue

    .
    Exosomes are hardy particles that contain molecules and molecular instructions to make various proteins, so they are easier to process and transfer than parental cells or cdc

    .

    cdc was first developed and described by Dr.
    Eduardo Marbán, Executive Director of the Smidt Heart Institute at Cedars-Sinai and Mark S.
    Siegel Family Foundation Distinguished Professor

    .
    They have been used in clinical trials for a variety of diseases, most recently Duchenne muscular dystrophy

    .

    One group of pigs had CDC-derived exosomes injected into their hearts, while the other group received a placebo
    .

    "Exosomes reduce the amount of scar tissue that forms in the injured area of ​​the heart, normalizing the heart rhythm without weakening the heart," said study co-author Dr.
    Marbán

    .

    Animals were evaluated with magnetic resonance imaging (MRI) and cardiac electrical stability testing
    .
    Four to six weeks after injection, experimental pigs treated with exosomes had significantly improved heart rates and reduced cardiac scarring

    .

    a new therapy

    In an editorial published in the same issue of the European Heart Journal, Yale University's Marine Cacheux, PhD, and Fadi G.
    Akar, PhD, summarize the pros and cons of various experimental gene and cell therapies for cardiac arrhythmias

    .
    Cedars-Sinai researchers "appear to have successfully combined the best properties of cell and gene therapy to address a major unmet clinical need," according to Cacheux and Akar

    .
    The authors note that the approach used by Cedars-Sinai is novel in repairing cardiac scars and describe the study as "a paradigm-shifting body of work.

    "

    The researchers plan to conduct more studies
    .

    "More research is needed to know that the benefits observed in this study persisted for longer periods of time," said James F.
    Dawkins, Ph.
    D.
    research scientist in veterinary medicine at Cedars-Sinai, first author of the study, "However, these preliminary results suggest the possibility of non-destructive replacement for the treatment of ventricular arrhythmias

    .
    "

    Funding: This study was funded by the National Institutes of Health under grant numbers 1K01HL133510-01A1, R01HL135866 and R01HL14750

    Journal Reference :

    1. James F.
      Dawkins, Ashkan Ehdaie, Russell Rogers, Daniel Soetkamp, ​​Jackelyn Valle, Kevin Holm, Lizbeth Sanchez, Ileana Tremmel, Asma Nawaz, Michael Shehata, Xunzhang Wang, Adityo Prakosa, Joseph Yu, Jennifer E.
      Van Eyk, Natalia Trayanova, Eduardo Marbán, Eugenio Cingolani.
      Biological substrate modification suppresses ventricular arrhythmias in a porcine model of chronic ischaemic cardiomyopathy .
      European Heart Journal , 2022; DOI: 10.
      1093/eurheartj/ehac042


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.